Abstract
Purpose To evaluate long-term outcomes of corneal collagen crosslinking (CXL) using riboflavin and UV-A irradiation and to determine when to repeat CXL.
Methods In this retrospective consecutive interventional case series 131 eyes of 131 patients (95 male, 36 female, mean age 29.7±11.4 years) between 2006 and 2016 received standard CXL (Dresden protocol, epithelium-off) for progressive keratoconus. Corrected distance visual acuity (CDVA) and corneal tomography (K1, K2, Kmax) were repeatedly recorded 1 year (n=103 eyes) to 10 years (n=44) postoperatively. Only one eye per patient was included. Paired t-test or Wilcoxon matched-pairs signed rank test was used for parametric and nonparametric data, respectively.
Results 1 to 3 years preoperatively, median K2 significantly increased by 1.1D (p<0.001). Postoperatively, median K2 increased by 0.1D after 1 year, then decreased over the remaining postoperative period by 0.85D (p=0.021). Median apical corneal thickness decreased by 16µm (p=0.012) after 5 years and then returned to preoperative values. Mean CDVA showed a significant improvement (decrease in logMAR 0.12 after 10 years, p=0.010). Kmax fluctuated without significant change. CXL non-responders, defined by a postoperative increase in Kmax>2D, increased from 16% after 5 to 33% after 10 years. Risk factors for non-response were young age, high astigmatism, thin cornea, and atopic dermatitis. 4 eyes were re-treated 3–4 years after first CXL without complications and keratoconus stabilized thereafter.
Conclusions CXL can slow or stop keratoconus progression. However, as the number of responders declines after 5 years, patients with risk factors may require re-treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by internal funds of the Department of Ophthalmology, University Hospitals Wuerzburg.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the medical faculty of the University of Wuerzburg gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of interest: None
Funding: Internal funds of the Department of Ophthalmology
Findings were presented at the ARVO meeting in Vancouver, Canada in May 2019 and at the CXL Experts Meeting in Zürich, Switzerland in November 2019.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
